CDC-RFA-PS22-2205: STRENGTHENING COLLABORATION BETWEEN TB CONTROL PROGRAMS AND AFFILIATED PARTNERS IN THE UNITED STATES
Closed
This grant is closed. A newer notice from the same program is forecast: Strengthening Collaboration Between Tuberculosis Control Programs and Affiliated Partners in the United States. (CDC-RFA-PS-27-0053). Status: Expected deadline May 21, 2027. It is in our archive of Centers for Disease Control - NCHHSTP notices from 2022.
Centers for Disease Control - NCHHSTP offered grants to any type of organization. It expected to make one award worth $1.6 million in total. Applications closed on June 6, 2022.
From the official notice on Grants.gov, last changed April 6, 2022. Checked November 7, 2026.
- Total funding$1.6 million
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | April 5, 2022 |
|---|---|
| Deadline | June 6, 2022 |
| Archived by Grants.gov | July 6, 2022 |
Who can apply
This opportunity was open to any type of organization.
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Section 317E (a) of the Public Health Service Act; 42 U.S.C. Section 247b-6(b).
Is this a realistic fit?
- Most of the program's money (96% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
The recipient will build on strengthening collaborations between TB control programs and their affiliated partners in the United States, to identify and forge collaborations that will accelerate TB elimination. The recipient will enhance communication, collaboration, consultation and conduct professional development for TB controllers, other stakeholders and key partners in the United States.
Who has won Project Grants and Cooperative Agreements for Tuberculosis Control Programs grants before
From fiscal 2021 to 2025, Project Grants and Cooperative Agreements for Tuberculosis Control Programs (93.116) awarded $416 million across 153 grant awards, an average of $2.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| California Department of Public Health | California | 3 | $44.3 million |
| Department of State Health Services | Texas | 2 | $35.0 million |
| Florida Department of Health | Florida | 4 | $25.2 million |
| City of New York | New York | 2 | $24.4 million |
| County of Los Angeles | California | 2 | $20.4 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, CDC-RFA-PS-27-0053, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-PS22-2205 still open?
No. It closed on June 6, 2022. A newer notice is forecast: CDC-RFA-PS-27-0053, expected deadline May 21, 2027.
Who can apply for STRENGTHENING COLLABORATION BETWEEN TB CONTROL PROGRAMS AND AFFILIATED PARTNERS IN THE UNITED STATES?
Centers for Disease Control - NCHHSTP accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for STRENGTHENING COLLABORATION BETWEEN TB CONTROL PROGRAMS AND AFFILIATED PARTNERS IN THE UNITED STATES?
Closed June 6, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $1.6 million in total for one award.
Who has won Project Grants and Cooperative Agreements for Tuberculosis Control Programs grants before?
The largest recipients over five fiscal years were California Department of Public Health, Department of State Health Services, Florida Department of Health. The program made 153 awards worth $416 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)